Recombinant Human CD83 protein, His & GST-tagged

• Cat.No.: CD83-1876H
• Product Overview: Recombinant Human CD83 aa. (Lys24~Val205) fused with N-terminal His & GST tag was produced in E. coli cells.

Specification

• Description: The protein encoded by this gene is a single-pass type I membrane protein and member of the immunoglobulin superfamily of receptors. The encoded protein may be involved in the regulation of antigen presentation. A soluble form of this protein can bind to dendritic cells and inhibit their maturation. Three transcript variants encoding different isoforms have been found for this gene.
• Source: E. coli
• Species: Human
• Tag: His&GST
• Form: Freeze-dried powder
• Molecular Mass: 57kDa as determined by SDS-PAGE reducing conditions.
• Protein length: Lys24~Val205
• Endotoxin: <1.0EU per 1ug (determined by the LAL method)
• Purity: >98%
• Characteristic: The isoelectric point is 7.
• Applications: Positive Control; Immunogen; SDS-PAGE; WB.
• Stability: The thermal stability is described by the loss rate of the target protein. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. (Referring from China Biological Products Standard, which was calculated by the Arrhenius equation.) The loss of this protein is less than 5% within the expiration date under appropriate storage condition.
• Storage: Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.
• Concentration: 200μg/mL
• Storage Buffer: 20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% sarcosyl, 5% Trehalose and Proclin300.
• Reconstitution: Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0mg/mL. Do not vortex.

Gene Information

• Gene Name: CD83 CD83 molecule [ Homo sapiens (human) ]
• Official Symbol: CD83
• Synonyms: SCNN1A; sodium channel epithelial 1 alpha subunit; BESC2; ENaCa; SCNEA; SCNN1; ENaCalpha; amiloride-sensitive sodium channel subunit alpha; alpha ENaC-2; alpha-ENaC; alpha-NaCH; amiloride-sensitive epithelial sodium channel alpha subunit; amiloride-sensitive sodium channel subunit alpha 2; epithelial Na(+) channel subunit alpha; nasal epithelial sodium channel alpha subunit; nonvoltage-gated sodium channel 1 subunit alpha; sodium channel, non voltage gated 1 alpha subunit; sodium channel, non-voltage-gated 1 alpha; sodium channel, nonvoltage-gated 1 alpha
• Gene ID: 9308
• mRNA Refseq: NM_001040280.1
• Protein Refseq: NP_001035370.1
• UniProt ID: Q01151

Reviews

03/16/2021

The experimental conditions are wide, and the experimental results are accurate and reproducible.

08/24/2020

The resulting strips are clear and bright, which greatly exceeds the expected results.

06/10/2020

CD83 activity is maintained for a very long time and can be maintained for a long time, which is very stable and reliable.

Q&As

Could CD83 be a target for immunotherapy?

Yes, CD83 can be targeted as immunotherapy. Immunotherapy for CD83 has been explored in several clinical trials with some efficacy.

Are there population differences in CD83 treatment?

It is unclear whether there is a population difference in CD83 treatment. However, due to factors such as individual differences and genetic polymorphisms, different populations may respond differently to treatment. Therefore, population-specific treatment strategies may need to be individually adapted and optimized.

What are possible aspects of future research on CD83?

Future research on CD83 may involve more in-depth molecular mechanism studies, optimization and improvement of CD83-based immunotherapy strategies, and research on combination with other immunotherapies or drugs.

Is there a relationship between CD83 and other immune checkpoint molecules?

CD83 interacts and regulates with other immune checkpoint molecules. Together, they are involved in the regulation of the immune response.

Is CD83 expression regulated by other molecules?

Yes, CD83 expression is regulated by a variety of molecules, including cytokines, transcription factors, and epigenetic modifications.

What is the therapeutic approach for CD83?

Current treatments for CD83 mainly include immunotherapy and gene therapy. Immunotherapy against CD83 works primarily by modulating the function of dendritic cells and T cells.